A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1/PD-L1 bispecific antibody, in participants with advanced solid tumors.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have a cancer that did not respond to standard therapy and has spread to another part(s) of the body
Participant must be willing to have new tumor tissue biopsies (doctor removes a small amount of tissue) during the study as long as it does not cause undue risks to health
Participant must be willing to use highly effective birth control
Participants Must Not:
Participant must not have certain infections such as hepatitis or tuberculosis or HIV that is not well controlled or received certain types of vaccines in the last 30 days
Participant must not have moderate to severe heart disease or heart problems as a result of exposure to certain chemotherapy
Participant must not have cancer of the central nervous system that is not stable
Participant must not have certain diseases that affect immune system, such as autoimmune vasculitis
Participant must not use high doses or increasing doses of corticosteroids or other drugs to suppress the immune system
Participant must not have disorders of the bowel such as bowel blockage, inflammation of the bowel, surgical removal of large parts of the bowel, or evidence of certain types of lung disease or inflammation
Participant must not be pregnant or breastfeeding
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo